Shares of Emergent Biosolutions Inc. (NYSE:EBS) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $26.76 and last traded at $26.77, with a volume of 273,184 shares trading hands. The stock had previously closed at $27.60.

A number of research firms have recently issued reports on EBS. Zacks Investment Research cut Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 2nd. Cowen and Company reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research report on Sunday, April 17th. Chardan Capital reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research report on Monday, May 2nd. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research report on Wednesday, June 22nd. Finally, Singular Research lowered their target price on Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, June 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $40.00.

The firm has a 50-day moving average price of $30.30 and a 200 day moving average price of $36.05. The stock has a market cap of $1.09 billion and a P/E ratio of 19.22.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.01. The business earned $101.49 million during the quarter, compared to analysts’ expectations of $111.20 million. During the same period in the prior year, the company earned $0.36 earnings per share. The business’s quarterly revenue was down 19.5% on a year-over-year basis. Equities research analysts expect that Emergent Biosolutions Inc. will post $0.89 EPS for the current year.

In other Emergent Biosolutions news, Director Jerome M. Hauer sold 3,134 shares of the business’s stock in a transaction that occurred on Thursday, May 19th. The stock was sold at an average price of $41.22, for a total transaction of $129,183.48. Following the completion of the sale, the director now directly owns 20,085 shares of the company’s stock, valued at approximately $827,903.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director George A. Joulwan sold 4,700 shares of the business’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $44.12, for a total value of $207,364.00. Following the sale, the director now directly owns 20,785 shares of the company’s stock, valued at $917,034.20. The disclosure for this sale can be found here.

A number of hedge funds recently modified their holdings of the company. Dimensional Fund Advisors LP raised its stake in shares of Emergent Biosolutions by 6.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,911,645 shares of the biopharmaceutical company’s stock worth $76,485,000 after buying an additional 112,452 shares in the last quarter. Matarin Capital Management LLC acquired a new position in shares of Emergent Biosolutions during the fourth quarter worth $7,953,000. California Public Employees Retirement System increased its position in shares of Emergent Biosolutions by 5.1% in the fourth quarter. California Public Employees Retirement System now owns 104,000 shares of the biopharmaceutical company’s stock worth $4,161,000 after buying an additional 5,000 shares during the last quarter. Bank of Montreal Can increased its position in shares of Emergent Biosolutions by 346.9% in the fourth quarter. Bank of Montreal Can now owns 93,100 shares of the biopharmaceutical company’s stock worth $3,725,000 after buying an additional 72,266 shares during the last quarter. Finally, Cornerstone Capital Management Holdings LLC. increased its position in shares of Emergent Biosolutions by 5.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 57,927 shares of the biopharmaceutical company’s stock worth $2,317,000 after buying an additional 3,227 shares during the last quarter.

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.